Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Nanoparticle-mediated pulmonary drug delivery : state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. / Huang, Zheng; Klodzinska, Sylvia Natalie; Wan, Feng; Nielsen, Hanne Morck.
In: Drug Delivery and Translational Research, Vol. 11, 2021, p. 1634–1654.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Nanoparticle-mediated pulmonary drug delivery
T2 - state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections
AU - Huang, Zheng
AU - Klodzinska, Sylvia Natalie
AU - Wan, Feng
AU - Nielsen, Hanne Morck
PY - 2021
Y1 - 2021
N2 - Recalcitrant respiratory tract infections caused by bacteria have emerged as one of the greatest health challenges worldwide. Aerosolized antimicrobial therapy is becoming increasingly attractive to combat such infections, as it allows targeted delivery of high drug concentrations to the infected organ while limiting systemic exposure. However, successful aerosolized antimicrobial therapy is still challenged by the diverse biological barriers in infected lungs. Nanoparticle-mediated pulmonary drug delivery is gaining increasing attention as a means to overcome the biological barriers and accomplish site-specific drug delivery by controlling release of the loaded drug(s) at the target site. With the aim to summarize emerging efforts in combating respiratory tract infections by using nanoparticle-mediated pulmonary delivery strategies, this review provides a brief introduction to the bacterial infection-related pulmonary diseases and the biological barriers for effective treatment of recalcitrant respiratory tract infections. This is followed by a summary of recent advances in design of inhalable nanoparticle-based drug delivery systems that overcome the biological barriers and increase drug bioavailability. Finally, challenges for the translation from exploratory laboratory research to clinical application are also discussed and potential solutions proposed.
AB - Recalcitrant respiratory tract infections caused by bacteria have emerged as one of the greatest health challenges worldwide. Aerosolized antimicrobial therapy is becoming increasingly attractive to combat such infections, as it allows targeted delivery of high drug concentrations to the infected organ while limiting systemic exposure. However, successful aerosolized antimicrobial therapy is still challenged by the diverse biological barriers in infected lungs. Nanoparticle-mediated pulmonary drug delivery is gaining increasing attention as a means to overcome the biological barriers and accomplish site-specific drug delivery by controlling release of the loaded drug(s) at the target site. With the aim to summarize emerging efforts in combating respiratory tract infections by using nanoparticle-mediated pulmonary delivery strategies, this review provides a brief introduction to the bacterial infection-related pulmonary diseases and the biological barriers for effective treatment of recalcitrant respiratory tract infections. This is followed by a summary of recent advances in design of inhalable nanoparticle-based drug delivery systems that overcome the biological barriers and increase drug bioavailability. Finally, challenges for the translation from exploratory laboratory research to clinical application are also discussed and potential solutions proposed.
KW - Respiratory tract bacterial infections
KW - Biofilms
KW - Intracellular infections
KW - Chronic pulmonary diseases
KW - Pulmonary drug delivery
KW - Nanotechnology
U2 - 10.1007/s13346-021-00954-1
DO - 10.1007/s13346-021-00954-1
M3 - Journal article
C2 - 33694082
VL - 11
SP - 1634
EP - 1654
JO - Drug Delivery and Translational Research
JF - Drug Delivery and Translational Research
SN - 2190-393X
ER -
ID: 261219652